Patents Issued in January 2, 2018
  • Patent number: 9855266
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: January 2, 2018
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon, Yi Zhu
  • Patent number: 9855267
    Abstract: Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: January 2, 2018
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Perla Breccia, Christopher A. Luckhurst, Roland W. Bürli, Andrew J. Stott
  • Patent number: 9855268
    Abstract: Compounds of the formula I in which R1 and R2 have the meanings indicated in claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: January 2, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Guenter Hoelzemann, Michel Calderini, Ansgar Wegener, Oliver Poeschke
  • Patent number: 9855269
    Abstract: The invention provides a method of inhibiting angiogenesis in a patient by administering a compound of formula (I): wherein R1 R2 and R3 are as defined herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 2, 2018
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Terry Crawford, Seth F. Harris, Steven R. Magnuson, Chudi Nbdubaku, Lan Wang
  • Patent number: 9855270
    Abstract: Described herein are methods and compositions for treating an ER-related disease condition characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator. Also described herein are methods of treating hormone resistant-estrogen receptor (ER) positive breast cancers characterized by a mutation in the ESR1 gene by administering an estrogen receptor modulator.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 2, 2018
    Assignee: GENENTECH, INC.
    Inventors: Jeffrey J. Hager, James D. Joseph, Jing Qian, Nicholas D. Smith, Edna Chow Maneval, Debasish F. Roychowdhury, Lori Friedman, Deepak Sampath
  • Patent number: 9855271
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: January 2, 2018
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Vladimir Khlebnikov
  • Patent number: 9855272
    Abstract: Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:
    Type: Grant
    Filed: August 23, 2016
    Date of Patent: January 2, 2018
    Assignee: Samumed, LLC
    Inventors: John Hood, Sunil Kumar Kc, David Mark Wallace
  • Patent number: 9855273
    Abstract: Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The disclosed methods include administering to an individual in need of such treatment a composition that may include an IRAK1/4 inhibitor. In other aspects, the method may include administration of a BLC2 inhibitor.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: January 2, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Daniel Starczynowski, Garrett W. Rhyasen
  • Patent number: 9855274
    Abstract: Phenoxy acetic acids and phenyl propionic acids and their use in treating type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of PPAR? and may be useful for treating conditions mediated by the same.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: January 2, 2018
    Assignee: vTv Therapeutics LLC
    Inventors: Per Sauerberg, Pavel Pihera, Zdenek Polivka, Miroslav Havranek, Ingrid Pettersson, John Patrick Mogensen
  • Patent number: 9855275
    Abstract: The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: January 2, 2018
    Assignee: Epizyme, Inc.
    Inventors: Kevin W. Kuntz, Richard Chesworth, Kenneth W. Duncan, Heike Keilhack, Natalie Warholic, Christine Klaus, Sarah K. Knutson, Timothy J. N. Wigle, Masashi Seki, Syuji Shirotori, Satoshi Kawano
  • Patent number: 9855276
    Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: January 2, 2018
    Assignee: The General Hospital Corporation
    Inventor: David R. Elmaleh
  • Patent number: 9855277
    Abstract: The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: January 2, 2018
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventor: Patricio Manuel Viera Araújo Soares Da Silva
  • Patent number: 9855278
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 2, 2018
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 9855279
    Abstract: Methods and kits for treating oral mucositis are disclosed. The treatment comprises administering to a patient in need thereof a Reactive Oxygen Species scavenger in a pharmaceutically acceptable formulation.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: January 2, 2018
    Assignee: GALERA LABS, LLC
    Inventors: David M. Rothstein, Chris Murphy, Vivien Wong, Glenn Kazo
  • Patent number: 9855280
    Abstract: The present application provides a composition comprising a core formed by gold nanoparticle, a compound of Formula (I): wherein dashed lines in Formula (I) represent (i) with or without an attachment of benzol group, (ii) a delocalized bond where shown within a ring; R1 is hydrogen or a halogen; R2 is a linker selected from C6-20 alkyl or polyethylene glycol; R3 is C1-20 alkyl, C1-20 substituted alkyl, hexadecanyl amido, pyridinyl, benzyl or pyrimidinyl; and a compound of Formula (II): wherein dashed lines, R1, R2 and R3 are defined as in Formula (II), and M is a metal. The composition has an inhibition ability against a cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignee: NATIONAL DONG HWA UNIVERSITY
    Inventors: Ivan Jyh Biau Lin, Tina H. T. Hsu, Shiu-Huey Chou
  • Patent number: 9855281
    Abstract: A composition for enhancing libido of a pharmaceutically effective amount of a libido-enhancing therapeutic of (5S,10R,13S,17S)-13-methyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula I), (3S,5S,10R,13S,17S)-3-hydroxy-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula II), (5S,10S,13S,17S)-17-hydroxy-13-methyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (Formula III), isomers thereof, analogs thereof, or combinations thereof, and a pharmaceutically acceptable carrier. A method of enhancing libido, by administering the composition to an individual in need of an enhanced libido, and enhancing libido in the individual or animal which is male or female. A method of enhancing libido, by administering the composition of the present invention to an individual at an age when libido and sexual desire have naturally decreased, and enhancing libido in the individual.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 2, 2018
    Assignee: Scott Freeman Consultant, LLC
    Inventor: Scott Freeman
  • Patent number: 9855282
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: January 2, 2018
    Assignee: Laboratoire HRA-Pharma
    Inventors: Delphine Levy, Erin Gainer
  • Patent number: 9855283
    Abstract: The present invention is about a pharmaceutical composition, an oral preparation, and an injection preparation containing a G protein-coupled Receptor19 (GPCR19) agonist, specifically sodium taurodeoxycholate (HY2191) and its derivative, as an active ingredient for preventing or treating allergic skin diseases. The present invention is also about an external preparation and a cosmetic composition containing said pharmaceutical composition for preventing and improving allergic skin diseases. The said pharmaceutical composition shows an excellent efficacy in treating and improving allergic dermatitis compared with the steroid ointments or immunosuppressive ointments currently used. The said pharmaceutical composition reduces the level of serum IgE, which is a major factor causing allergic dermatitis, increases TH1 cytokine alleviating allergic dermatitis and reduces TH2 cytokine that exacerbates allergic dermatitis.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: January 2, 2018
    Assignee: SHAPERON Inc.
    Inventors: Seung Yong Seong, Youn Hee Kim
  • Patent number: 9855284
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: January 2, 2018
    Assignee: Pop Test Oncology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 9855285
    Abstract: The present invention relates to a method of inhibiting the upregulation of the expression of the proinflammatory cytokine interleukin-22 (IL-22) in activated and differentiated human T-cells, said upregulation being induced by administration of a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor. The method comprises administering, either sequentially to or simultaneously with the administration of the PDE4 inhibitor, a vitamin D receptor agonist in an amount sufficient to inhibit the upregulation of IL-22 expression.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: January 2, 2018
    Assignee: LEO PHARMA A/S
    Inventor: Paola Lovato
  • Patent number: 9855286
    Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: January 2, 2018
    Assignee: Gruenenthal GmbH
    Inventors: Stefanie Frosch, Klaus Linz, Klaus Schiene
  • Patent number: 9855287
    Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: January 2, 2018
    Assignees: LIFE TECHNOLOGIES CORPORATION, THE JOHNS HOPKINS UNIVERSITY
    Inventors: Brian Agnew, David Graham, Upinder Singh, Scott Grecian
  • Patent number: 9855288
    Abstract: The present invention includes compositions and methods of making and using a dietary supplement manufactured from one or more natural polysaccharides previously incubated with a probiotic bacteria in a bioreactor system, wherein the bacteria process the polysaccharides and the resulting processed polysaccharide are provided in the nutritional supplement.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: January 2, 2018
    Assignee: MANNATECH, INCORPORATED
    Inventor: Robert A. Sinnott
  • Patent number: 9855289
    Abstract: The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: January 2, 2018
    Assignee: Metro International Biotech, LLC
    Inventors: Karl D. Normington, David A. Sinclair, David J. Livingston, James M. McKearin, Bruce Szczpankiewicz, Jonathan N. Kremsky
  • Patent number: 9855290
    Abstract: Compounds and compositions useful for the treatment of liver diseases and methods of treating liver diseases are disclosed. The compounds of the invention specifically interact with heteromers of cannabinoid receptors as compared to monomers or homodimers. The invention also relates to methods of screening for compounds useful for the treatment of liver diseases and to methods of screening for diacylglycerol lipase inhibitors.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: January 2, 2018
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Lakshmi A. Devi, Raphael Rozenfeld
  • Patent number: 9855291
    Abstract: Novel monoclonal antibodies that specifically bind to KAAG1 are described. In some embodiments, the antibodies block the biological activity of KAAG1 and are useful in composition in certain cancers, more particularly in cancers that have increased cell surface expression of KAAG1, such as ovarian, renal, lung, colorectal, breast, brain, and prostate cancer, as well as melanoma. The invention also relates to cells expressing the monoclonal antibodies and antigen binding fragments such as humanized and chimeric antibodies. Additionally, methods of detecting and treating cancer using the antibodies and fragments are also disclosed.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: January 2, 2018
    Assignee: ADC Therapeutics SA
    Inventors: Gilles Bernard Tremblay, Mario Filion, Traian Sulea
  • Patent number: 9855292
    Abstract: The current invention discloses novel approaches to help individuals defend against headaches and body pains with orally-delivered cyanocobalamin, methylcobalamin, adenosylcobalamin, and combinations thereof. Original clinical research conducted by the inventor on almost 2,000 humans yielded surprising and unexpected results showing differences in the frequency and severity of pains in the head and the body favoring cyanocobalamin patients over placebo. In one FDA-approved Phase III study on 1,551 patients, 4.4 percent of headaches and body pains were rated as “Severe” in the cyanocobalamin, group versus 11.5 percent in the placebo group. Once inside the body, cyanocobalamin is converted to methylcobalamin and adenosylcobalamin, but not to hydroxocobalamin.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: January 2, 2018
    Inventor: Ernest Timothy Armstrong
  • Patent number: 9855293
    Abstract: Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: January 2, 2018
    Assignee: INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY
    Inventor: Du Woon Kim
  • Patent number: 9855294
    Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 2, 2018
    Assignee: Gelesis, LLC
    Inventors: Hassan Heshmati, Eyal S. Ron, Alessandro Sannino, Yishai Zohar
  • Patent number: 9855295
    Abstract: A topical ophthalmic composition comprised of povidone-iodine 0.01% to 10.0% combined with a steroid or non-steroidal anti-inflammatory drug. This solution is useful in the treatment of active infections of at least one tissue of the eye (e.g., conjunctiva and cornea) from bacterial, mycobacterial, viral, fungal, or amoebic causes, as well as treatment to prevent such infections in appropriate clinical settings (e.g. corneal abrasion, postoperative prophylaxis, post-LASIK/LASEK prophylaxis). Additionally the solution is effective in the prevention of infection and inflammation in the post-operative ophthalmic patient.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: January 2, 2018
    Assignee: CLARUS CLS HOLDINGS, LLC
    Inventors: C. Michael Samson, Bo Liang, Joseph A. Capriotti
  • Patent number: 9855296
    Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: January 2, 2018
    Assignee: The McLean Hospital Corporation
    Inventors: Anne M. Cataldo, Bruce M. Cohen
  • Patent number: 9855297
    Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: January 2, 2018
    Assignee: CELLECTIS
    Inventors: Philippe Duchateau, André Choulika, Laurent Poirot
  • Patent number: 9855298
    Abstract: The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes a method of conditioning a patient prior to a T cell therapy, wherein the conditioning involves administering a combination of cyclophosphamide and fludarabine.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 2, 2018
    Assignees: Kite Pharma, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Adrian Bot, Jeffrey S. Wiezorek, William Go, Rajul Jain, James N. Kochenderfer, Steven A. Rosenberg
  • Patent number: 9855299
    Abstract: Disclosed herein axe methods and compositions for treating retinal degeneration, such as occurs in retinitis pigmentosa and age-related macular degeneration, using descendents of marrow adherent stem cells that have been engineered to express an exogenous Notch intracellular domain.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: January 2, 2018
    Assignee: SanBio, Inc.
    Inventors: Casey C. Case, Toru Kawanishi, Noriyuki Kuno
  • Patent number: 9855300
    Abstract: The invention relates to a composition and method used for injuries treatment with a surprisingly therapeutic effect. This composition comprises a population of cells derived from human umbilical cord blood which expresses one of the following markers: CD34, CD45, and CD31; a population of CD34+ derived endothelial cells; and a biomimetic gel, preferably fibrin. The method for obtaining the composition comprises the derivation of a population of endothelial cells from CD34+ cells and then a co-culture of a CD34+ cells with CD34+-derived endothelial cells within a biomimetic gel.
    Type: Grant
    Filed: November 28, 2011
    Date of Patent: January 2, 2018
    Assignee: CRIOESTAMINAL, SAÚDE E TECNOLOGIA, SA.
    Inventors: Lino Da Silva Ferreira, Dora Cristina Dos Santos Pedroso
  • Patent number: 9855301
    Abstract: A laminated graft fabricated from human birth tissue material comprising at least two amniotic membranes, or at least two chorionic membranes, or at least one amniotic membrane and at least one chorionic membrane, and at least one morselized placental composition to form a human birth tissue laminate graft. Methods of processing human birth tissue material to form a laminated graft are also provided. Additionally, methods for treating a wound or defect and methods of promoting regeneration of diseased or damaged tissue are provided.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: January 2, 2018
    Assignee: BioDLogics LLC
    Inventor: Timothy R. Brahm
  • Patent number: 9855302
    Abstract: Provided herein are methods of treatment and/or prevention of cancer by manipulation of commensal microflora. In particular, the amount, identity, presence, and/or ratio of microflora (e.g., gut microflora) in a subject is manipulated to facilitate one or more co-treatments.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 2, 2018
    Assignee: The University of Chicago
    Inventors: Thomas F. Gajewski, Ayelet Sivan, Leticia Corrales
  • Patent number: 9855303
    Abstract: Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: January 2, 2018
    Assignee: Seres Therapeutics, Inc.
    Inventors: Gregory McKenzie, Mary-Jane Lombardo McKenzie, David N. Cook, Marin Vulic, Geoffrey von Maltzahn, Brian Goodman, John Grant Aunins, Matthew R. Henn, David Arthur Berry, Jonathan Winkler
  • Patent number: 9855304
    Abstract: The invention relates to the use of Lactobacillus rhamnosus strain CNCM 1-3690 for reducing body fat accumulation and treating disorders resulting therefrom, such as overweight, obesity, and obesity-related disorders.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: January 2, 2018
    Assignees: Compagnie Gervais Danone, Biopolis S.L.
    Inventors: Gianfranco Grompone, Daniel Ramon Vidal, Patricia Martorell Guerola, Salvador Genoves Martinez, Josefa Ortiz Serrano, Silvia Llopis Pla, Nuria Gonzalez Martinez
  • Patent number: 9855305
    Abstract: The present invention relates to a pharmaceutical composition containing a combination of vitamins, specific salts of calcium, magnesium, and iron, probiotics and prebiotics, which prevents the occurrence of adverse effects associated with long-term use of proton-pump inhibitors (PPIs). This effect is achieved by restoring all nutrient deficiencies and rectifying the intestinal flora imbalance caused by this type of drugs, particularly in patients with gastroesophageal reflux disease and Zollinger-Ellison syndrome.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: January 2, 2018
    Assignee: Companion Therapeutics LLC
    Inventors: Julio César Villamil Torres, Camilo Rey Ferro
  • Patent number: 9855306
    Abstract: A Portulaca oleracea L. extract feed additive and a preparation method thereof are provided. The Portulaca oleracea L. extract feed additive takes a Portulaca oleracea L. extract and a carrier as raw materials. The Portulaca oleracea L. extract is prepared by the ultrasonic auxiliary water extraction. The preparation method of the present invention has less raw material waste, high activity component content in the extract and acquisition rate of the extractum, which facilitates improving the effect efficiency and reducing production cost. The Portulaca oleracea L. extract feed additive as a natural plant feed additive is capable of improving the animal's metabolism, increasing the animal's relative weight gain, improving the animal's survival rate, reducing the disease incidence of various diarrhea symptoms, decreasing the animal's stress response and increasing the animal productivity.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: January 2, 2018
    Assignee: Shanghai Zhao Xiang Biological Technology Co., LTD
    Inventors: Jiaming Chen, Xuefeng Chen, Ling Lu, Ting Shu, Zili Chen, Ziqiang Chen, Danrong Zheng, Shunjie Huang
  • Patent number: 9855307
    Abstract: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the management of inflammatory mucosal diseases of both viral and non-viral origin.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: January 2, 2018
    Assignee: Izun Pharmaceuticals Corporation
    Inventors: William Z. Levine, Aron J. Saffer, Mina Fran
  • Patent number: 9855308
    Abstract: The present invention provides a nutraceutical composition, a process for the preparation of the nutraceutical composition useful for amelioration of peri- and post-menopausal symptoms in women. The nutraceutical composition is stable, directly compressible, water soluble, free flowing form having particle size not more than 2.0 ?m comprising extract of Trigonella foenum-graecum, at least one bioavailable form of magnesium and vitamin E. The present invention also provides a method of treating ameliorating, treating and/or preventing peri- and post-menopausal discomforts in a subject suffering from peri- or post-menopausal symptoms comprising administering to the subject a therapeutically effective amount of the nutraceutical composition.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: January 2, 2018
    Assignee: AKAY FLAVOURS & AROMATICS PVT. LTD.
    Inventors: Krishnakumar Illathu Madhavamenon, Balu Paulose Maliakel, Shamshad Begum Saddapalli, Jayalakshmi Hosakere Krishnamurthy, Geetha Kalaiah, Vasundhara Mariappa, Suresha Sanaba Venkataiah
  • Patent number: 9855309
    Abstract: Compositions for the treatment of sores, wounds, burns and other traumatized dermal tissues and skin injuries comprising Boswellia gum, gel, resin or extract, Tea Tree oil (Melaleuca oil), an Aloe gel, resin, latex or extract and Lavender oil. The composition may be incorporated into a medical device such as a wound dressing or bandage, or formulated into a topical preparation such as an ointment, lotion or cream.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: January 2, 2018
    Assignees: Nutriquine N.V., JAMP Pharma Corporation
    Inventors: Guy Chamberland, Peter Bollen
  • Patent number: 9855310
    Abstract: The present invention relates to Coix seed oil extracted from Semen Coicis, pharmaceutical preparations thereof, and the use thereof in the treatment of tumors and inflammation. Specifically, the Coix seed oil contains 8 triglyceride ingredients in the following mass percentages: trilinolein 4.87-6.99%, 1-olein-2,3-dilinolein 13.00-18.69%, 1-palmitin-2,3-dilinolein 5.25-7.54%, 1,3-diolein-2-linolein 13.23-19.02%, 1-palmitin-2-linolein-3-olein 10.26-14.75%, 1,3-dipalmitin-2-linolein 2.28-3.28%, triolein 14.44-20.76%, and 1-palmitin-2,3-diolein 8.06-11.58%.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: January 2, 2018
    Assignee: ZHEJIANG KANGLAITE GROUP CO., LTD.
    Inventor: Dapeng Li
  • Patent number: 9855311
    Abstract: Herbal compound formulations using herbs curcuma longa (turmeric), ocimum sanctum (holy basil) and emblica officinalis (amla) in their natural forms and a method of packaging the same for dietary supplement as tablets, wafers, capsules and as teabags where the packaging of individual dosages and the outer packaging may use visual display of color that represents the proportion and presence of different herbs in the herbal compound.
    Type: Grant
    Filed: March 25, 2012
    Date of Patent: January 2, 2018
    Inventor: Tara Chand Singhal
  • Patent number: 9855312
    Abstract: Disclosed herein are compositions of GHRH agonists and peptides, and methods to treat disorders, such as ischemia and reperfusion injury. In one embodiment, a method of treating a reperfusion injury in a subject in need may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In additional embodiment, a method of promoting vasculogenesis in a mammal may involve administering a therapeutically effective amount of at least one GHRH agonist peptide to the subject. In a further embodiment, a method of promoting differentiation of mesenchymal stem cells into endothelial cells may involve contacting mesenchymal stem cells with at least one GHRH agonist peptide.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: January 2, 2018
    Assignees: UNIVERSITY OF MIAMI, THE UNITED STATES OF AMERICA, REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Andrew V. Schally, Joshua M. Hare, Norman L. Block, Samirah A. Gomes, Rosemeire M. Kanashiro-Takeuchi
  • Patent number: 9855313
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: January 2, 2018
    Assignee: MUSC Foundation for Research Development
    Inventors: Gautam Ghatnekar, Robert Gourdie, Jane Jourdan
  • Patent number: 9855314
    Abstract: The present invention relates to compositions and methods comprising administering gene modifiers for treating ocular disease.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: January 2, 2018
    Assignee: The Schepens Eye Research Insititute, Inc.
    Inventor: Neena B. Haider
  • Patent number: 9855315
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a heart failure and a method for screening a therapeutic agent for preventing or treating a heart failure. The pharmaceutical composition of the present disclosure comprises the CCN5 or CCN2?CT protein, or a genetic carrier comprising a nucleotide sequence encoding the CCN5 or the CCN2?CT protein, exhibiting dramatic prevention or treatment efficacies on a heart failure even without surgical treatments accompanied with transplanting a donor heart.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: January 2, 2018
    Assignee: BETHPHAGEN INC.
    Inventors: Woo Jin Park, Pyoung Oh Yoon, Dong Kwon Yang